Evidence map›Paper›PMID 39980938›Full record

ReviewKidney medicine2025

Metabolomics to Identify Unclassified Uremic Toxins: A Comprehensive Literature Review.

Raymond Vanholder, Griet Glorieux, Angel Argiles, Stéphane Burtey, Gerald Cohen, Flore Duranton, Laetitia Koppe, Ziad A Massy, Alberto Ortiz, Rosalinde Masereeuw and 2 more

Abstract readReview
In one paragraph

Review in Kidney medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Alterations of Plasma Metabolites Associated with Sickle Cell Trait.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Article
  4. Review
  5. Review
  6. Article
  7. Review
  8. A guide to uraemic toxicity.Nature reviews. Nephrology · 2026
    Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Raymond VanholderNephrology Section, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.
Griet GlorieuxNephrology Section, Department of Internal Medicine and Pediatrics, Ghent University Hospital, Ghent, Belgium.
Angel ArgilesRD Néphrologie, Montpellier, France.
Stéphane BurteyC2VN, Aix-Marseille Université, INSERM, INRAE, Marseille, France.
Gerald CohenDepartment of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Flore DurantonRD Néphrologie, Montpellier, France.
Laetitia KoppeDepartment of Nephrology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Université de Lyon, Lyon, France.
Ziad A MassyInserm Unit 1018, Team 5, CESP, Hôpital Paul Brousse, Paris-Sud University (UPS), Villejuif, France.
Alberto OrtizDepartment of Nephrology and Hypertension, IIS-Fundacion Jimenez Diaz UAM, Madrid, Spain.
Rosalinde MasereeuwDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands.
Dimitrios StamatialisAdvanced Organ Bioengineering and Therapeutics, Technical Medical Centre, Faculty of Science and Technology, University of Twente, Enschede, The Netherlands.
Joachim JankowskiInstitute for Molecular Cardiovascular Research (IMCAR), RWTH Aachen University, Aachen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A comprehensive review of known uremic retention molecules goes back to more than 10 years ago and did not consider metabolomic analyses. The present analysis searches for as of yet unclassified solutes retained in chronic kidney disease (CKD) by analyzing metabolites associated with relevant outcomes of CKD. This untargeted metabolomics-based approach is compared with a conventional targeted literature search. For the selected molecules, the literature was screened for arguments regarding toxic (harmful), beneficial, or neutral effects in experimental or clinical studies. Findings were independently crosschecked. In total, 103 molecules were selected. No literature on any effect was found for 55 substances, 3 molecules had no significant effect, and 13 others showed beneficial effects. For the remaining 32 compounds, we found at least one report of a toxic effect. Whereas 62.5% of the compounds with at least one study on a toxic effect was retrieved via the bottom-up approach, 69.2% of the substances originating from metabolomics-based approaches showed a beneficial effect. Our results suggest that untargeted metabolomics offer a more balanced view of uremic retention than the targeted approaches, with higher chances of revealing the beneficial potential of some of the metabolites.

Indexed as

Chronic kidney diseasemetabolomicstoxicityuremic toxin

Identifiers

PMID39980938
PMCPMC11841090

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.